F. D. Lublin, S. C. Reingold, and J. A. Cohen, Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.

G. Filippini, D. Giovane, C. Vacchi, and L. , Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev, p.8933, 2013.

, Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results, Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group, vol.56, pp.1496-504, 2001.

H. Panitch, A. Miller, and D. Paty, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study, Neurology, vol.63, issue.10, pp.1788-95, 2004.

J. A. Cohen, G. R. Cutter, and J. S. Fischer, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, vol.59, issue.5, pp.679-87, 2002.

O. Andersen, I. Elovaara, and M. Färkkilä, Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.75, issue.5, pp.706-716, 2004.

X. Montalban, S. L. Hauser, and L. Kappos, Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, N Engl J Med, vol.376, issue.3, pp.209-229, 201719.
URL : https://hal.archives-ouvertes.fr/hal-01793440

K. Hawker, P. O'connor, and M. S. Freedman, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-71, 2009.

R. Lonergan, K. Kinsella, and M. Duggan, Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? Mult Scler Houndmills Basingstoke Engl, vol.15, pp.1528-1559, 2009.

J. Bonenfant, E. Bajeux, and V. Deburghgraeve, Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?, Eur J Neurol, vol.24, issue.2, pp.237-281, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01484970

A. Scalfari, A. Neuhaus, and M. Daumer, Early relapses, onset of progression, and late outcome in multiple sclerosis, JAMA Neurol, vol.70, issue.2, pp.214-236, 2013.

A. Scalfari, A. Neuhaus, and A. Degenhardt, The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability, Brain J Neurol, vol.133, pp.1914-1943, 2010.

M. Novotna, P. Soldán, M. M. , A. Zeid, and N. , Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis, Neurology, vol.85, issue.8, pp.722-731, 2015.

G. Bsteh, R. Ehling, and A. Lutterotti, Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study, PloS One, vol.11, issue.7, p.158978, 2016.

S. B. Glad, H. I. Nyland, and J. H. Aarseth, Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway, Mult Scler Houndmills Basingstoke Engl, vol.15, issue.8, pp.942-50, 2009.

R. Bergamaschi, C. Berzuini, and A. Romani, Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis, J Neurol Sci, vol.189, issue.1-2, pp.13-21, 2001.

E. Leray, J. Yaouanq, L. Page, and E. , Evidence for a two-stage disability progression in multiple sclerosis, Brain J Neurol, vol.133, pp.1900-1913, 2010.